This is only the second biosimilar product to receive EU marketing authorization from the European Commission.
Biopartners in-licensed Valtropin from LG Life Sciences and has commercialization rights for the drug in Europe, Japan and other parts of Asia. Biopartners developed the drug in combination with LG Life Sciences.
The company is also developing a sustained release version of Valtropin that is currently in phase III clinical trials.
“Valtropin will provide pediatric endocrinologists with a more cost-effective treatment option for growth disorders compared to the currently marketed growth hormone preparations and this in turn will allow us to treat more patients, which is great news,” said Professor Paul Saenger of the Albert Einstein College of Medicine in New York.